• News
  • Stock Screener
  • Small Caps
  • Guru portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·DOCS
Share

Doximity, Inc. Stocks

$ 18.97Last Updated 15.05.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

$ 4.39B

$ 18.97
Key Takeaways

Risk factor

High price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

29.01.2026 16:40

BofA picks 10 smid-cap stocks that may beat Wall Street's 4Q expectations

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of DOCS is 27 and suggests 40% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.05.2026 17:18

Main in small-caps: BuzzFeed deal, bets on AI boom, forecast from BNP Paribas AM

16.05.2026 13:01

Highlights of the week: Trump in China, Cerebras IPO, UK crisis

16.05.2026 04:20

US inflation could soar to 6%, economists have allowed. Their forecast has been halved

16.05.2026 03:33

Ford has its worst collapse in 15 months after rallying 20%. It's even been called a meme stock

16.05.2026 02:27

The stock market approached its highest valuation in history - the days of the dot-com bubble

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026